Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
21.98
+1.98 (9.90%)
At close: May 29, 2026, 4:00 PM EDT
21.91
-0.07 (-0.32%)
After-hours: May 29, 2026, 7:40 PM EDT
Company Description
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Tango Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Malte Peters |
Contact Details
Address: 201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States | |
| Phone | 857 320 4900 |
| Website | tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Malte Peters M.D. | President, Chief Executive Officer and Director |
| Dr. Barbara L. Weber M.D. | Founder and Executive Chair |
| Daniella Beckman CPA | Executive Officer |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research and Development |
| Prof. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Matthew Gall M.B.A. | Chief Financial Officer |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
| Julie Fogarty | Vice President of Legal and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | 8-K | Current Report |
| May 6, 2026 | SCHEDULE 13G | Filing |